EFG Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

EFG Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24,328	Closed	-$3.04M	–	195
2024 Q3	$3.04M	Sell	24,328 -2,275	-9%	-$315K	0.51%	69
2024 Q2	$4.2M	Sell	26,603 -2,221	-8%	-$285K	0.73%	31
2024 Q1	$3.73M	Buy	28,824 +3,690	+15%	+$452K	0.64%	44
2023 Q4	$2.42M	Buy	25,134 +2,422	+11%	+$232K	0.46%	77
2023 Q3	$2.75M	Sell	22,712 -1,582	-7%	-$179K	0.65%	54
2023 Q2	$2.78M	Buy	24,294 +2,336	+11%	+$301K	0.6%	56
2023 Q1	$3.03M	Sell	21,958 -1,859	-8%	-$241K	0.67%	50
2022 Q4	$3.03M	Buy	23,817 +2,423	+11%	+$281K	0.68%	51
2022 Q3	$2.36M	Buy	+21,394	New	+$2.16M	0.55%	62

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EFG Asset Management's SRPT Position: Q4 2024 in Review

EFG Asset Management sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 24,328 shares — an estimated $3.04M sold.

EFG Asset Management first reported a position in SRPT in Q3 2022 and held it in 9 quarters. The position peaked at $4.2M in Q2 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

EFG Asset Management reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
EFG Asset Management sold 24,328 Sarepta Therapeutics shares in Q4 2024, an estimated $3.04M.
EFG Asset Management first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 9 quarters.
EFG Asset Management's Sarepta Therapeutics position peaked at $4.2M in Q2 2024.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on EFG Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.